目的 觀察艾迪注射液聯(lián)合帕博利珠單抗治療晚期非小細(xì)胞肺癌的臨床療效。方法 選取2019年1月—2022年5月在南通市海門區(qū)人民醫(yī)院腫瘤內(nèi)科住院治療的120例肺癌患者，采用隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各60例。對照組靜脈滴注帕博利珠單抗，2mg/kg，藥物給藥時間為30min以上，每3周給藥1次。治療組在對照組的基礎(chǔ)上靜脈滴注艾迪注射液，50mL/次，1次/d。兩組均治療6周。觀察兩組的臨床療效，比較兩組生活質(zhì)量評分（FACT-L）、卡氏功能狀態(tài)量表評分（KPS）、CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺及白細(xì)胞介素-6（IL-6）、血管內(nèi)皮生長因子（VEGF）、轉(zhuǎn)化生長因子-β₁（TGF-β₁）、γ干擾素（IFN-γ）水平。結(jié)果 治療后，治療組患者疾病控制率是83.33%，顯著高于對照組的60.00%（P<0.05）。治療后，治療組咳痰、胸悶、胸痛、痰中有血緩解時間均顯著短于對照組（P<0.05）。治療后，兩組患者FACT-L評分、KPS評分均較治療前顯著升高（P<0.05）；治療后，治療組FACT-L評分、KPS評分均高于對照組（P<0.05）。治療后，兩組CD3⁺、CD4⁺、CD4⁺/CD8⁺均較治療前顯著升高，CD8⁺顯著降低（P<0.05）；治療后，治療組T淋巴細(xì)胞亞群指標(biāo)改善優(yōu)于對照組（P<0.05）。治療后，兩組患者IL-6、VEGF、TGF-β₁水平均較治療前顯著降低，而IFN-γ顯著升高（P<0.05）；治療后治療組血清炎性因子水平改善優(yōu)于對照組（P<0.05）。治療后，治療組不良反應(yīng)發(fā)生率是6.67%，顯著低于對照組的18.33%（P<0.05）。結(jié)論 艾迪注射液聯(lián)合帕博利珠單抗治療晚期非小細(xì)胞肺癌有一定療效，可提高患者免疫功能，有效降低炎性因子水平，明顯提高患者生活質(zhì)量，值得推廣。

Objective To investigate the clinical study of Aidi Injection combined with pembrolizumab in treatment of advanced non-small cell lung cancer. Methods A total of 120 cases of lung cancer hospitalized in the Department of Oncology of Nantong Haimen People’s Hospital from January 2019 to May 2022 were selected. All patients were divided into control group and treatment group by random number table method, with 60 cases in each group. Patients in the control group were iv administered with Pembrolizumab Injection, 2 mg/kg, intravenously for more than 30 minutes, once every 3 weeks. Patients in the control group were iv administered with Aidi Injection on the basis of the control group, 50 mL/time, once daily. Both groups were treated for 6 weeks. The clinical efficacy of the two groups was observed. The quality of life score (FACT-L), KPS score, CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ indexes, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), transforming growth factor-β₁ (TGF-β₁), interferon-γ (IFN-γ) were compared between two groups. Results After treatment, the disease control rate of the treatment group was 83.33%, which was significantly higher than that of the control group (60.00%, P < 0.05). After treatment, the remission time of expectoration, chest tightness, chest pain, blood in sputum and other symptoms in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, the FACT-L score and KPS score of the two groups were significantly higher than those before treatment (P< 0.05). After treatment, the FACT-L score and KPS score of the treatment group were higher than those of the control group (P < 0.05). After treatment, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ indexes of the two groups were significantly increased compared with those before treatment, while CD8⁺ was significantly decreased (P < 0.05). After treatment, the improvement of T lymphocyte subsets in the treatment group was better than that in the control group (P < 0.05). After treatment, the levels of IL-6, VEGF and TGF-β1 in the two groups were significantly decreased, while IFN-γ was significantly increased (P < 0.05). After treatment, the improvement of serum inflammatory factors in treatment group was better than that in control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 6.67%, which was significantly lower than 18.33% in the control group (P< 0.05). Conclusion Aidi Injection combined with pembrolizumab has a certain effect in treatment of advanced non-small cell lung cancer, and can improve the immune function of patients, effectively reduce the level of inflammatory factors, and improve the life quality of patients significantly, which is worthy of promotion.

R979.1